secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K/A
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001516551-23-000071
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Schwab and Grayson to board; Grayson gets $350k bonus and large performance RSUs
--------------------------------------------------------------------------------

- Paul Grayson appointed director with a $350,000 sign-on bonus.
- 18.1M performance RSUs vest on market cap milestones: $125M, $250M, $400M, or $500M+ exit.
- Additional 43.4M performance RSUs subject to stockholder approval of plan amendment.
- Andrew Schwab appointed to board and compensation committee; standard non-employee director compensation.
- 7.4M stock options granted to non-employee directors; up to 17.6M more pending plan amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000071/0001516551-23-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000071/skye-20230815.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer